Compare GE Vernova Inc (GEV) vs Novavax Inc (NVAX) Price & Performance

GE Vernova (GEV) trades at $1,038, down 2.63% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The company demonstrates strong profitability with 23.81% net income margin and 83.23% ROE, though valuation metrics appear elevated with P/E of 30.84 and EV/EBITDA of 109.82. Recent earnings showed volatility with Q1 2026 beating expectations by a wide margin, while the company prepares for Q2 2026 results amid significant AI-driven power demand growth.

The outlook remains positive with analyst consensus strongly bullish (21 buy ratings, 0 sell) and $1,260 price target representing 21% upside. Key opportunities include AI data center power demand and $11 billion investment push, while risks include wind segment pressures and elevated valuation multiples that may limit near-term upside potential despite strong fundamentals.

Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.

The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.